Similarly, robust phenotypic benefit in SMA mice was accomplished by promoting SMN2 exon 7 inclusion using antisense oligonucleotides targeting intronic splicing silencers [32], [33]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.